Market Overview

Why Autolus Therapeutics Is Trading Higher Today

Why Autolus Therapeutics Is Trading Higher Today

Autolus Therapeutics (NASDAQ: AUTL) shares are trading higher on Wednesday after SunTrust Robinson Humphrey initiated coverage on the stock with a Buy rating and announced a price target of $38 per share.

Autolus Therapeutics is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and others.

Autolus Therapeutics shares were trading up 6.32% at $15.90 on Wednesday during the time of publication. The stock has a 52-week high of $16.99 and a 52-week low of $3.

Latest Ratings for AUTL

Jul 2020JP MorganInitiates Coverage OnOverweight
Jul 2020SunTrust Robinson HumphreyInitiates Coverage OnBuy
Jun 2020MizuhoMaintainsBuy

View More Analyst Ratings for AUTL
View the Latest Analyst Ratings


Related Articles (AUTL)

View Comments and Join the Discussion!

Posted-In: why it's movingPrice Target Initiation Analyst Ratings

Latest Ratings

NGMPiper SandlerInitiates Coverage On30.0
ETNBPiper SandlerInitiates Coverage On54.0
FLXNOppenheimerInitiates Coverage On19.0
ALTPiper SandlerInitiates Coverage On80.0
CBAYPiper SandlerInitiates Coverage On12.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at